Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 323 Cr.
- Current Price ₹ 208
- High / Low ₹ 318 / 189
- Stock P/E 32.3
- Book Value ₹ 74.3
- Dividend Yield 0.00 %
- ROCE 11.8 %
- ROE 9.05 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Promoter holding has increased by 5.00% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
- Promoter holding has decreased over last 3 years: -35.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 36 | 55 | 74 | 101 | 122 | 137 | 156 | |
| 33 | 50 | 65 | 86 | 105 | 122 | 139 | |
| Operating Profit | 3 | 5 | 9 | 15 | 17 | 15 | 17 |
| OPM % | 7% | 9% | 12% | 15% | 14% | 11% | 11% |
| 1 | 1 | 1 | 1 | 2 | 2 | 1 | |
| Interest | 1 | 1 | 2 | 3 | 2 | 3 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Profit before tax | 1 | 4 | 7 | 12 | 15 | 12 | 14 |
| Tax % | 27% | 28% | 26% | 25% | 25% | 27% | 26% |
| 1 | 3 | 6 | 9 | 11 | 8 | 10 | |
| EPS in Rs | 5.10 | 13.60 | 27.50 | 8.97 | 7.97 | 5.44 | 6.43 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 3% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 44 | 90 | 100 |
| 9 | 11 | 23 | 26 | 8 | 45 | 0 | |
| 7 | 13 | 14 | 13 | 12 | 15 | 25 | |
| Total Liabilities | 21 | 31 | 49 | 60 | 78 | 166 | 141 |
| 4 | 4 | 4 | 16 | 16 | 17 | 17 | |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 16 | 16 |
| 16 | 22 | 37 | 44 | 61 | 133 | 101 | |
| Total Assets | 21 | 31 | 49 | 60 | 78 | 166 | 141 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 2 | 7 | 9 | 7 | -15 | -26 | 36 | |
| -1 | -5 | -7 | -3 | -3 | -23 | -10 | |
| -1 | -1 | -2 | -3 | 23 | 74 | -32 | |
| Net Cash Flow | 0 | 1 | 0 | 2 | 5 | 25 | -6 |
| Free Cash Flow | 1 | 2 | 4 | 3 | -18 | -30 | 27 |
| CFO/OP | 103% | 160% | 127% | 69% | -65% | -150% | 233% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 70 | 64 | 55 | 71 | 92 | 73 |
| Inventory Days | 90 | 80 | 96 | 93 | 88 | 118 | 90 |
| Days Payable | 80 | 105 | 69 | 45 | 29 | 36 | 10 |
| Cash Conversion Cycle | 85 | 45 | 91 | 102 | 129 | 173 | 153 |
| Working Capital Days | 54 | 21 | 47 | 35 | 112 | 104 | 109 |
| ROCE % | 32% | 34% | 37% | 29% | 13% | 12% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Customers Number |
|
|||||
| Bio-Coal Production (Subsidiary) MT |
||||||
| Installed Production Capacity (Iodine Derivatives) MTPA |
||||||
| Number of APIs in Portfolio Number |
||||||
| Number of Countries (Export Footprint) Number |
||||||
| Number of Employees Number |
||||||
| Number of Iodine Derivatives in Portfolio Number |
||||||
| Annual Production Volume (Iodine Derivatives) MT |
||||||
| Capacity Utilization (Derived) % |
||||||
| Domestic Market Share (Iodine Market) % |
||||||
| EU-REACH Registrations Number |
||||||
Extracted by Screener AI
Documents
Announcements
-
Outcome of Board Meeting
29 May 2026 - Infinium Pharmachem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
-
General Updates
20 May 2026 - GPCB revoked closure order; Infinium resumes manufacturing at Sojitra plant from May 20, 2026.
-
Structural Digital Database
29 April 2026 - Submitted SDD compliance certificate for year ended March 31, 2026.
-
Disruption of Operations
14 April 2026 - GPCB ordered temporary closure of Sojitra plant; company must submit Rs. 2 lakh bank guarantee.
-
Reply to Clarification- Financial results
13 April 2026 - Clarified FY25 results format and single-segment reporting to NSE.
Annual reports
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT REC
-
Mar 2024Transcript PPT
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis